Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo

We aimed to identify potent biliverdin reductase (BVRA) inhibitors as a novel concept for the treatment of severe unconjugated hyperbilirubinemia. 1280 FDA-approved compounds were screened in vitro for their ability to inhibit human and rat BVRA activity and 26 compounds were identified as BVRA in...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Rep
Päätekijät: van Dijk, Remco, Aronson, Sem J., de Waart, Dirk R., van de Graaf, Stan F., Duijst, Suzanne, Seppen, Jurgen, Elferink, Ronald Oude, Beuers, Ulrich, Bosma, Piter J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431759/
https://ncbi.nlm.nih.gov/pubmed/28490767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-01602-w
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia